Overview
4D Molecular Therapeutics Q3 revenue missed analyst expectations
Net income for Q3 missed analyst estimates
Company entered strategic partnership with Otsuka, receiving $85 mln upfront cash
Outlook
4DMT expects cash runway into 2H 2028, supported by Otsuka partnership and equity offering
4DMT expects interim data from AEROW Phase 1 trial by year-end 2025
Result Drivers
Research and development expenses were $49.4 million for the third quarter of 2025, as compared to $38.5 million for the third quarter of 2024
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $90,000 | $287,900 (7 Analysts) |
Q3 Net Income | Miss | -$56.88 mln | -$56.20 mln (4 Analysts) |
Q3 Operating Income | Slight Beat* | -$61.19 mln | -$61.60 mln (5 Analysts) |
Q3 Basic EPS | -$1.01 | ||
Q3 Operating Expenses | $61.28 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for 4D Molecular Therapeutics Inc is $34.50, about 69.6% above its November 7 closing price of $10.50
Press Release: ID:nGNX5qGQ2W
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)